Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079440 | 0.79 | KEAP1 (0.52) | KEAP1NFE2L2L3MBTL1GLO1PTGS1 | |
| SCHEMBL157836 | 0.79 | KEAP1 (0.47) | KEAP1NFE2L2L3MBTL1GLO1PTGS1 | |
| SCHEMBL5015655 | 0.78 | EP300 (0.46) | KEAP1NFE2L2L3MBTL1GLO1PTGS1 | |
| SCHEMBL5015626 | 0.78 | KEAP1 (0.46) | KEAP1NFE2L2L3MBTL1GLO1PTGS1 | |
| SCHEMBL5015645 | 0.78 | KEAP1 (0.46) | KEAP1NFE2L2L3MBTL1GLO1PTGS1 | |
| SCHEMBL3641678 | 0.75 | KEAP1 (0.43) | KEAP1NFE2L2L3MBTL1GLO1PTGS1 | |
| SCHEMBL5143144 | 0.75 | KEAP1 (0.54) | KEAP1NFE2L2L3MBTL1GLO1HTT | |
| SCHEMBL1045149 | 0.74 | — | — | |
| SCHEMBL3789124 | 0.74 | KEAP1 (0.59) | KEAP1NFE2L2L3MBTL1GLO1KIF11 | |
| SCHEMBL6678119 | 0.74 | KEAP1 (0.45) | KEAP1NFE2L2L3MBTL1GLO1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2020-04-02 | — | — | US | disclosed |
| EP-3406596-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco Inc. (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-20180265454-A1 | Method for Producing 4-Oxoquinoline Compound | JAPAN TOBACCO INC. (JP) | 2018-09-20 | — | — | US | disclosed |
| US-20150299104-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-1992607-B9 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. | 2015-06-25 | — | — | US | disclosed |
| EP-1992607-B1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20130310595-A1 | Method for Producing 4-Oxoquinoline Compound | JAPAN TOBACCO INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-20130172344-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. | 2013-07-04 | — | — | US | disclosed |
| CN-101437785-A | Process for preparing 4-oxoquinoline compounds | JAPAN TOBACCO INC (JP) | 2009-05-20 | — | — | CN | disclosed |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1992607-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | Japan Tobacco, Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| CN-100375742-C | 4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors | JAPAN TOBACCO INC (JP) | 2008-03-19 | — | — | CN | disclosed |
| US-7176220-B2 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | JAPAN TOBACCO INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20060217413-A1 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | disclosed |
| CN-1692101-A | 4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors | JAPAN TOBACCO INC (JP) | 2005-11-02 | — | — | CN | disclosed |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1564210-A1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299104-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | IMPDH1, IMPDH2, CDK20 | KEAP1 4068/4885NFE2L2 3150/4885L3MBTL1 1563/4885 |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | NQO2, ACE, CDK20 | KEAP1 2172/4885NFE2L2 3503/4885L3MBTL1 2446/4885 |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | KEAP1 3393/4885NFE2L2 2541/4885L3MBTL1 1404/4885 |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | KEAP1 3393/4885NFE2L2 2541/4885L3MBTL1 1404/4885 |
| US-20130310595-A1 | Method for Producing 4-Oxoquinoline Compound | IMPDH1, IMPDH2, CDK20 | KEAP1 4068/4885NFE2L2 3150/4885L3MBTL1 1563/4885 |
| US-20130172344-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | IMPDH1, CDKL4, IMPDH2 | KEAP1 3475/4885NFE2L2 2857/4885L3MBTL1 827/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | KEAP1 3281/4885NFE2L2 2550/4885L3MBTL1 1478/4885 |
| US-20180265454-A1 | Method for Producing 4-Oxoquinoline Compound | IMPDH1, IMPDH2, CDK20 | KEAP1 4068/4885NFE2L2 3150/4885L3MBTL1 1563/4885 |
| US-20060217413-A1 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | IMPDH1, CDKL4, IMPDH2 | KEAP1 3475/4885NFE2L2 2857/4885L3MBTL1 827/4885 |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | IMPDH1, IMPDH2, TYMP | KEAP1 3857/4885NFE2L2 3293/4885L3MBTL1 1132/4885 |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | IMPDH1, IMPDH2, CDK20 | KEAP1 4068/4885NFE2L2 3150/4885L3MBTL1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.